Clarifying the Risks and Benefits of JAKI in RA
Released On
December 18, 2024
Expires On
December 18, 2025
Media Type
Internet
Completion Time
45 minutes
Specialty
Rheumatology, Primary Care
Topics
Rheumatoid Arthritis
CME INFO
This activity is jointly provided by Global Education Group (GLOBAL) and Platformq Health Education, LLC (PQHE).
Acknowledgement
This activity is supported by an independent educational grant from AbbVie Inc.
Date of Release/Expiration
This activity was released on December 18, 2024 and is valid until December 18, 2025. Requests for credit must be made no later than December 18, 2025.
Credit Available
Physicians - maximum of .75 AMA PRA Category 1 Credit™
Target Audience
The educational design of this activity addresses the needs of rheumatology and primary care clinicians (MDs/DOs/NPs/PAs) who treat patients with RA, including rheumatology nursing professionals and other allied healthcare professionals on the care team.
Program Overview
The treatment landscape for rheumatoid arthritis (RA) changed after clinical trials showed that treatment outcomes for Janus kinase (JAK) inhibitors were comparable and, in some cases, superior to those of biologics. But JAK inhibitors have also been associated with serious adverse events, including major adverse cardiac events (MACE), malignancies, thrombosis, and infections, which are identified in a boxed warning on their FDA-approved labelling. Thus, clinicians must stay up to date with the latest JAK inhibitor safety and efficacy data, and understand how and when to use these agents to manage patients with RA while ensuring safety.
Join a panel of rheumatologists to explore the critical role played by the JAK-STAT pathway in the pathophysiology of RA. Panelists will review JAK inhibitor efficacy and safety data, including cardiovascular, thrombotic, malignancy, and infection risks. Real-life experiences with JAKi and key trial results will be shared and discussed.
Educational Objectives
After completing this activity, the participant should be better able to:
- Differentiate JAK inhibitors based on their selectivity profiles
- Summarize efficacy data for JAK inhibitors for RA
- Discuss the latest understanding of the safety of JAK inhibitors for RA, with a focus on cardiovascular, VTE, malignancy, and infection risks
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated Time to Complete
This activity should take approximately 45 minutes to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
Technical Support
For any technical issues or issues with your CME Certificate, please contact MedLive at 877-394-1306 or at [email protected].